Accumulating evidence suggests that urokinase plasminogen activator (uPA) is involved in vascular remodeling and lumen stenosis after angioplasty and stenting. We have shown previously that increased uPA expression greatly promotes neointima formation and inward arterial remodeling after balloon injury. To evaluate the role of inflammation in early mechanisms responsible for inward arterial remodeling induced by uPA and elucidate the mechanisms of remodeling, we characterized changes in the expression profiles of 8,799 genes in injured rat carotid arteries 1 and 4 days after recombinant uPA treatment compared to vehicle. We used a standard model of the balloon catheter injury of the rat carotid followed by periadventitial application to the injured vessel of either uPA dissolved in Pluronic gel, or plain gel. Vessels were harvested and analyzed by immunohistochemistry, morphometry, microarray gene expression profiling and quantitative RT-PCR. Periadventitial application of uPA significantly reduced lumen size and vessel area encompassed by the external elastic lamina at both 1 and 4 days after treatment. Inflammatory cells accumulated in the arterial adventitia at both 1 and 4 days after uPA treatment. On the 4th day, increases in the areas and arterial cell numbers of all arterial layers were found. Among 79 differentially expressed known genes 1 day after uPA application, 12 proinflammatory genes, including TNF-α and TACE, and 15 genes related to mitochondrial metabolism and oxidative stress regulation were identified. Four days after injury in uPA-treated arteries, 3 proinflammatory and 2 oxidation-related genes were differentially expressed. We conclude that uPA likely promotes inward arterial remodeling by regulating oxidative stress and inflammation after arterial injury.

Keywords:
Urokinase plasminogen activator, Inward arterial remodeling, Inflammation, Oxidative stress, Microarray
1.
Clowes AW, Reidy MA: Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia – a review. J Vasc Surg 1991;13:885–891.
2.
Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK: A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992;86:III47–III52.
3.
Schwartz RS: Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodelling. Am J Cardiol 1998;81:14E–17E.
4.
Carmeliet P, Moons L, Herbert JM, Crawley J, Lupu F, Lijnen R, Collen D: Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997;81:829–839.
5.
Plekhanova OS, Parfyonova YV, Bibilashvily RS, Stepanova VV, Erne P, Bobik A, Tkachuk VA: Urokinase plasminogen activator enhances neointima growth and reduces lumen size in injured carotid arteries. J Hypertens 2000;18:1065–1069.
6.
Collen D: Ham-Wasserman lecture: Role of the plasminogen system in fibrin-homeostasis and tissue remodelling. Hematology 2001;1:1–9.
7.
Parfyonova Ye, Plekhanova O, Solomatina M, Naumov V, Bobik A, Berk BC, Tkachuk V: Contrasting effects of urokinase and tissue-type plasminogen activators on neointima formation and vessel remodeling early after arterial injury. J Vasc Res 2004;41:268–276.
8.
Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA, Wilcox JN: Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 2001;104:2228–2235.
9.
Shah PK: Inflammation, neointimal hyperplasia, and restenosis: s the leukocytes roll, the arteries thicken. Circulation 2003;107:2175–2177.
10.
Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, Paloscia L, Materazzo G, D’Annunzio E, Conti P, Chiarelli F, Cuccurullo F, Mezzetti A: Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 2001;21:327–334.
11.
Plekhanova O, Parfyonova Y, Bibilashvily R, Domogatskii S, Stepanova V, Gulba DC, Agrotis A, Bobik A, Tkachuk V: Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms. Atherosclerosis 2001;159:297–306.
12.
Brooks AI, Stein CS, Hughes SM, Heth J, McCray PM Jr, Sauter SL, Johnston JC, Cory-Slechta DA, Federoff HJ, Davidson BL: Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci USA 2002;99:6216–6221.
13.
Li C, Hung Wong W: Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2001;2:RESEARCH0032.
14.
Welle S, Brooks AI, Thornton CA: Computational method for reducing variance with Affymetrix microarrays. BMC Bioinformatics 2002;3:23.
15.
Hoffmann R, Seidl T, Dugas M: Profound effect of normalization on detection of differentially expressed genes in oligonucleotide microarray data analysis. Genome Biol 2002;3:RESEARCH0033.
16.
Korshunov V, Nikonenko T, Tkachuk V, Brooks AI, Berk BC: Interleukin-18 and macrophage migration inhibitory factor are associated with increased carotid intima-media thickening. Arterioscler Thromb Vasc Biol 2006;26:295–300.
17.
Loppnow H, Westphal E, Buchhorn R, Wessel A, Werdan K: Interleukin-1 and related proteins in cardiovascular disease in adults and children. Shock 2001;16(suppl 1):3–9.
18.
Li H, Liang J, Castrillon DH, DePinho RA, Olson EN, Liu ZP: FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription. Mol Cell Biol 2007;27:2676–2686.
19.
Kubica J, Kozinski M, Krzewina-Kowalska A, Zbikowska-Gotz M, Dymek G, Sukiennik A, Piasecki R, Bogdan M, Grzesk G, Chojnicki M, Dziedziczko A, Sypniewska G:Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int J Mol Med 2005;16:173–180.
20.
Menshikov M, Plekhanova O, Cai H, Chalupsky K, Parfyonova Y, Bashtrikov P, Tkachuk V, Berk BC: Urokinase plasminogen activator stimulates vascular smooth muscle cell proliferation via redox-dependent pathways. Arterioscler Thromb Vasc Biol 2006;26:801–807.
21.
Solomatina MA, Plekhanova OS, Menshikova MY, Ratner EI, Tkachuk VA, Parfyonova YV: Urokinase increases the content and activity of matrix metalloproteinases 2 and 9 during in vivo constrictive arterial remodeling. Bull Exp Biol Med 2005;139:283–286.
22.
Pawlak K, Pawlak D, Mysliwiec M: Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis 2007;190:199–204.
23.
Haj-Yehia A, Nassar T, Sachais BS, Kuo A, Bdeir K, Al-Mehdi AB, Mazar A, Cines DB, Higazi AA: Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo. FASEB J 2000;14:1411–1422.
24.
Mori E, Komori K, Yamaoka T, et al: Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation 2002;105:2905–2910.
25.
Boyle JJ: Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005;3:63–68.
26.
Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236–241.
27.
Böse D, Leineweber K, Konorza T, Zahn A, Bröcker-Preuss M, Mann K, Haude M, Erbel R, Heusch G: Release of TNFα during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis. Am J Physiol Heart Circ Physiol 2007;292:H2295–H2299.
28.
Seki N, Bujo H, Jiang M, Shibasaki M, Takahashi K, Hashimoto N, Saito Y: A potent activator of PPARalpha and gamma reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits. Atherosclerosis 2005;178:1–7.
29.
Ono H, Ichiki T, Fukuyama K, Iino N, Masuda S, Egashira K, Takeshita A: AMP-response element-binding protein mediates tumor necrosis factor-alpha-induced vascular smooth muscle cell migration. Arterioscler Thromb Vasc Biol 2004;24:1634–1639.
30.
Selzman CH, Meldrum DR, Cain BS, Meng X, Shames BD, Ao L, Harken AH: Interleukin-10 inhibits postinjury tumor necrosis factor-mediated human vascular smooth muscle proliferation. J Surg Res 1998;80:352–356.
31.
Voisard R, Voglic S, Baur R, Susa M, Koenig W, Hombach V: Leukocyte attack in a 3D human coronary in-vitro model. Coron Artery Dis 2001;12:401–411.
32.
Overall CM, Lopez-Otin C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657–672.
33.
Siwik DA, Colucci WS: Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 2004;9:43–51.
34.
Kuzuya M, Iguchi A: Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 2003;10:275–282.
35.
Korshunov VA, Berk BC: Flow-induced vascular remodeling in the mouse: a model for carotid intima-media thickening. Arterioscler Thromb Vasc Biol 2003;23:2185–2191.
36.
Berk BC: Redox signals that regulate the vascular response to injury. Thromb Haemost 1999;82:810–817.
37.
Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995;25:155–161.
38.
Berk BC: Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 2001;81:999–1030.
39.
Nunes GL, Robinson K, Kalynych A, King SB III, Sgoutas DS, Berk BC: Vitamins C and E inhibit O2– production in the pig coronary artery. Circulation 1997;96:3593–3601.
40.
Cao D, Mizukami IF, Garni-Wagner BA, Kindzelskii AL, Todd RF 3rd, Boxer LA, Petty HR: Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium. J Immunol 1995;154:1817–1829.
41.
Sitrin RG, Pan PM, Harper HA, Todd RF 3rd, Harsh DM, Blackwood RA: Clustering of urokinase receptors (uPAR; CD87) induces proinflammatory signaling in human polymorphonuclear neutrophils. J Immunol 2000;165:3341–3349.
42.
Nakano H, Nakajima A, Sakon-Komazawa S, Piao JH, Xue X, Okumura K: Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ 2006;13:730–737.
43.
Nishikawa T, Araki E: Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal 2007;9:343–353.
44.
Ungvari Z, Wolin MS, Csiszar A: Mechanosensitive production of reactive oxygen species in endothelial and smooth muscle cells: role in microvascular remodeling? Antioxid Redox Signal 2006;8:1121–1129.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.